Long-Term Xeljanz for UC; AGA Drops Obesity Drug Guidelines; PPIs & Cystic Fibrosis?

(MedPage Today) -- Health-related quality-of-life outcomes continued to be favorable with maintenance tofacitinib (Xeljanz) for ulcerative colitis (UC) during up to 6 years of follow-up, regardless of treatment history, responder status, or remission...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news